explore -WSS

explore

author：hotspot 2025-08-26 01:32:35 - browse：5523

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Abortion pill case raises question: who can sue the FDA?

hotspot

WSS

Plastic surgeons increase patient psychiatric screenings

The Readout: Lenmeldy, GLP

Supreme Court mifepristone arguments center on docs' right to sue

Washington mulls new rules to avert another Change Healthcare

Readout Newsletter: Bluebird, CVS, Contineum

Washington mulls new rules to avert another Change Healthcare

knowledge

explore

hotspot

How one medical school became remarkably diverse

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Novavax promises a turnaround & Lilly roils the obesity market

Methadone treatment changes are coming. Do they go far enough?

DIEP, the 'gold standard' of breast reconstruction, is under threat

AstraZeneca to buy developer of next

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: mifepristone case, GLP

Drug repurposing or repositioning? The language matters

Donor acceptance rates hint at racial, gender bias in heart transplants: study

hotspot

Readout Newsletter: Merck, Vertex, and Viking updates

Steward Health Care has deal to sell doctor network to UnitedHealth

Orchard's therapy for neuron disease in children wins FDA approval

Decaf coffee targeted by food safety group under obscure FDA rule

Covid vaccine financial winners and losers, from Pfizer to Novavax

Baby aspirin cuts fat buildup in liver disease patients, in small study

hotspot

explore

explore

focus